Installation of a Second CyberKnife(R) Robotic Radiosurgery System in Vicenza Hospital

Vicenza, the First Facility to Have Offered CyberKnife Radiosurgery in Europe, Increases its Capacity to Treat More Cancer Patients with the Installation of a Second System

SUNNYVALE, California, November 1, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that Vicenza Hospital, Ospedale Civile San
Bortolo in Italy, has become the first European hospital to be equipped
with two CyberKnife(R) Robotic Radiosurgery Systems. The second System is
expected to begin treating patients before the end of the calendar year.

"The CyberKnife is able to deliver accurate radiosurgical treatments
quickly and easily anywhere in the body, making it the ideal treatment
option for the growing number of radiosurgery cases. With the installation
of a second CyberKnife System, we will be able to meet this increasing
demand for precise radiosurgical treatment throughout the body and to
treat a wider array of patients, including those who were previously
considered inoperable or poor surgical candidates due to old age and
associated medical condition, and those who seek an alternative to
surgery," said Professor Federico Colombo M.D., Director of the
Neurosurgical Department at Vicenza Hospital.

Vicenza Hospital, which is located in the Venetian region of Italy,
installed its first CyberKnife System in 2003, the first in Europe, and
has been using it mainly to treat arteriovenous malformations (AVM) and
benign tumors of the brain such as neuromas and meningiomas. The second
system will allow an increased number of patients to receive treatments
for both intracranial and extracranial tumors. "To date, Vicenza Hospital
has treated more than 2,300 patients with the CyberKnife System and the
hospital hopes to double the number of patients that benefit from
CyberKnife treatment," added Professor Federico Colombo.

With patient interest in CyberKnife radiosurgery and physician
referrals expanding exponentially, the addition of a second system at
Vicenza is representative of the growing number of CyberKnife Centers
purchasing and installing multiple systems worldwide.

"As the indications that can benefit from CyberKnife radiosurgery
continue to evolve, the demand for radiosurgery treatments within an
institution exceed the capacity of a single CyberKnife System," said
Vittorio Puppo, General Manager of Accuray EIMEA (Europe, India, Middle
East, Africa). "Vicenza Hospital's expansion is another example of
facilities that desire multiple CyberKnife Systems to manage growing
patient demand for treatment of tumors not only intracranially, but in the
lung, prostate, pancreas and liver."

About Vicenza Hospital

For more information, please visit www.ulssvicenza.it/.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body non-
invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time
throughout the treatment. This enables the CyberKnife System to deliver
high-dose radiation with pinpoint precision, which minimizes damage to
surrounding healthy tissue and eliminates the need for invasive head or
body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an
improved quality of life and a non-surgical treatment option for those
diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic
Radiosurgery System, which extends the benefits of radiosurgery to include
extracranial tumors, including those in the spine, lung, prostate, liver
and pancreas. To date, the CyberKnife System has been used to treat more
than 100,000 patients worldwide and currently more than 206 systems have
been installed in leading hospitals in the Americas, Europe and Asia. For
more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that
involve risks and uncertainties, including uncertainties associated with
the medical device industry. Except for the historical information
contained herein, the matters set forth in this press release, including
statements relating to clinical usage, clinical benefits, clinical
acceptance, anticipated number of patient treatments and multiple system
purchases are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements speak only as of the date the statements
are made and are based on information available at the time those
statements are made and/or management's good faith belief as of that time
with respect to future events. You should not put undue reliance on any
forward-looking statements. Important factors that could cause actual
performance and results to differ materially from the forward-looking
statements we make include: market acceptance of products; competing
products, the combination of our products with complementary technology;
and other risks detailed from time to time under the heading "Risk
Factors" in our report on Form 10-K for the 2010 fiscal year which has
been filed with the Securities and Exchange Commission on August, 31,
2010. The Company's actual results of operations may differ significantly
from those contemplated by such forward-looking statements as a result of
these and other factors. We assume no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.

Sancie Nakarat, Manager, EU Marketing of Accuray Incorporated, + 33-(0)-6-81-36-84-34, snakarat at accuray.com; or Fleur de Lempdes, Edelman Paris, + 33-(0)-1-56-69-75-23, fleur.delempdes at edelman.com, for Accuray Incorporated